publicações selecionadas
-
artigo académico
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3. Journal of Clinical Investigation. 2024
- Glucocorticoid receptor-dependent therapeutic efficacy of tauroursodeoxycholic acid in preclinical models of Spinocerebellar ataxia type 3 (IF: 19.47). The Journal of Clinical Investigation. 2024
- Profiling Microglia in a Mouse Model of Machado-Joseph Disease. Biomedicines. 2022
- Levetiracetam Treatment Leads to Functional Recovery after Thoracic or Cervical Injury of the Spinal Cord. Regenerative Medicine. 2021
- Polyglutamine spinocerebellar ataxias: emerging therapeutic targets. Expert Opinion on Therapeutic Targets. 2020
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors 2019
- Polyglutamine spinocerebellar ataxias - from genes to potential treatments.. Nature reviews. Neuroscience. 2017
-
artigo de revista
- Preclinical Assessment of Mesenchymal-Stem-Cell-Based Therapies in Spinocerebellar Ataxia Type 3. Biomedicines. 2021
- Dysregulation of autophagy and stress granule-related proteins in stress-driven Tau pathology. Cell Death and Differentiation. 2018
- Neuroprotective Effects of Creatine in the CMVMJD135 Mouse Model of Spinocerebellar Ataxia Type 3. Movement Disorders. 2018
- Combined therapy with m-TOR-dependent and -independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease. Neuroscience. 2016
- Serotonergic signalling suppresses ataxin 3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain. 2015
- Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph Disease. Antibiotics. 2015
- Secretome of Mesenchymal Progenitors from the Umbilical Cord Acts as Modulator of Neural/Glial Proliferation and Differentiation. Stem Cell Reviews and Reports. 2015
- The Role of the Mammalian DNA End-processing Enzyme Polynucleotide Kinase 3'-Phosphatase in Spinocerebellar Ataxia Type 3 Pathogenesis. 2015
- Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells. Human Molecular Genetics. 2015
- Lithium Chloride Therapy Fails to Improve Motor Function in a Transgenic Mouse Model of Machado-Joseph Disease. Cerebellum. 2014
- Selective impact of Tau loss on nociceptive primary afferents and pain sensation. Experimental Neurology. 2014
- Chronic Treatment with 17-DMAG Improves Balance and Coordination in A New Mouse Model of Machado-Joseph Disease. Neurotherapeutics. 2014
- The Secretome of Bone Marrow and Wharton Jelly Derived Mesenchymal Stem Cells Induces Differentiation and Neurite Outgrowth in SH-SY5Y Cells.. Stem Cells International. 2014
- Neuron-specific proteotoxicity of mutant ataxin-3 in C. elegans: Rescue by the DAF-16 and HSF-1 pathways. Human Molecular Genetics. 2011
- Absence of Ataxin-3 Leads to Enhanced Stress Response in C. elegans. Antibiotics. 2011
- ATX-3, CDC-48 and UBXN-5: A new trimolecular complex in Caenorhabditis elegans. Biochemical and Biophysical Research Communications. 2009
-
documento
- ATXN3-mediated deubiquitylation of splicing factors regulates neuronal mRNA splicing and tau isoform ratio ATXN3 regulates SRSF7 levels and Tau ratio 2023
- Unraveling the ATXN3 interactome: clues on its contribution for physiology and disease 2023
- Glucocorticoid Receptor as a Biomarker and Neuronal Therapeutic Target of a Disease-Improving Bile Acid in SCA3/MJD 2022
- The Glucocorticoid Receptor as a Biomarker and Neuronal Therapeutic Target of a Disease-Improving Bile Acid in SCA3/MJD 2022
- Nuclear ATXN3 DUB Physiological Substrates: Towards Understanding Their Role In The Context Of Machado-Joseph Disease 2022
- Role of the ubiquitin hydrolase ATXN3 in glioblastoma: a new tumor suppressor gene? 2022
- A comprehensive characterization of the cerebellar (dys)fucntion in Spinocerebellar Ataxia Type 3 2021
- Testing the Therapeutic Potential of Mesenchymal Stem Cells and Their Secretome in an Animal Model of Spinocerebellar Ataxia Type 3 2021
- Cerebellar neuronal dysfunction accompanies early motor symptoms in Spinocerebellar Ataxia Type 3 and is partially alleviated upon chronic citalopram treatment 2021
- Neuronal communication in Spinocerebellar Ataxia Type 3: a longitudinal characterization of the synapse 2020
- Cerebellar Dysfunction in Spinocerebellar Ataxia Type 3 2020
- Impact of astrocytic calcium suppression in the pathogenesis of Machado-Joseph disease 2020
- Pre-clinical study of mesenchymal stem cells transplantation and their secretive administration in an animal model of Spinocerebellat ataxia type 3 2020
- Impact of astrocytic calcium suppression in the pathogenesis of Machado Joseph disease 2019
- Pre-clinical assessment of Mesenchymal Stem cell-based therapies in Spinocerebellar ataxia type 3 2019
- A Glucorticoid receptor-dependent mechanism of bile acid action with therapeutic impact in polyglutamine disease. 2019
- A Glucorticoid receptor-dependent mechanism of bile acid action with therapeutic impact in polyglutamine disease 2019
- Regulation of neuronal mRNA splicing and Tau isoform ratio by ATXN3 through deubiquitylation of splicing factors 2019
- Microglial and astrocytic pathology in a mouse model of Machado-Joseph disease 2019
- Testing the therapeutic potential of mesenchymal stem cells and their secretome in an animal model of SCA3 2019
- Regulation of neuronal mRNA splicing and Tau isoform by ATXN3 in Spinocerebellar Ataxia Type-3 transgenic mice and patients. 2019
- Pre-clinical study of mesenchymal stem cells transplantation and their secretome administration in an animal model of Spinocerebellar ataxia type 3 2019
- Cerebellar Dysfunction in Spinocerebellar Ataxia Type 3 2019
- Regulation of neuronal mRNA splicing and of Tau isoforms ratio by ATXN3 through deubiquitylation of splicing factors 2019
- Study of Cerebellar circuits (dys)function in Spinocerebellar Ataxia type 3 2019
- Testing the therapeutical potential of mesenchymal stem cells and their secretome in an animal model of SCA3 2019
- Neuroprotective effects of creatine in the CMVMJD135 mouse model of spinocerebellar ataxia type 3 2018
- Serotonergic Modulation of Cerebellar Circuitry in Health and Spinocerebellar Ataxia Type 3 2018
- Study of Cerebellar Circuitry (Dys)function in MJD”; 2018
- TUDCA, a bile acid, improves the phenotype of Machado-Joseph disease models 2018
- Macromolecular interactions and posttranslational modifications acting as Machado-Joseph Disease modifiers 2017
- Neuroinflammation assessment in a transgenic mouse model of Machado-Joseph disease 2017
- Time and region-specific glial pathology in mouse model of Machado-Joseph disease 2017
- "Creatine food supplementation improves the phenotype and delays disease onset of the CMVMJD135 mouse model of Machado-Joseph disease" 2016
- Creatine-supplemented diet delays disease onset and improves the overall phenotype of the CMVMJD135 mouse model of MJD 2016
- "Combined therapy with m-TOR-dependent and –independent autophagy inducers causes neurotoxicity in a mouse model of Machado-Joseph disease" 2015
- "TUDCA reduces neuroinflammation and improves motor symptoms in a transgenic mouse model of Machado-Joseph disease" 2015
- “Lithium therapy fails to improve motor function in a transgenic mouse model of Machado-Joseph disease” 2015
- “Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells” 2014
- “Mesenchymal stem cells secretome: a new therapeutic tool for central nervous system repair?” 2014
- "Silencing of ATXN3 in neuroblastome cell lines: effects on cytoskeleton organization and cell adhesion” 2013
- “17-DMAG induces autophagy and delays disease progression in a mouse model of Machado-Joseph Disease” 2013
- “Ataxin-3 deubiquitylase contributes to neuronal differentiation through the modulation of alpha-5 integrin levels” 2013
- “Loss of function of the deubiquitylase Ataxin-3 affects differentiation, proliferation and cytoskeletal organization in neuronal cells through the modulation of alpha-5 integrin subunit levels” 2013
- “Loss of function of the deubiquitylase Ataxin-3 reduces alpha-5 integrin subunit levels and leads to an abnormal neuronal differentiation process” 2013
- “Overexpression of wild-type, expanded and catalytically inert ATXN3 in neuroblastome cell lines: effects on cytoskeleton organization and cell adhesion” 2013
- “Secretome of Mesenchymal progenitors of the umbilical cord: a mediator for neural/glial cells survival and differentiation?” 2013
- “Stable silencing of Ataxin-3 leads to abnormal differentiation in neuronal cells” 2013
- “Effects of mesenchymal stem cells secretome in different neuronal cultures” 2012
- "17-DMAG an HSP90 inhibitor improves the motor phenotype and neuropathology of a transgenic mouse model of Machado-Joseph Disease" 2012
- “17-DMAG an HSP90 inhibitor improves the phenotype of a transgenic mouse model of Machado-Joseph Disease” 2012
- “17-DMAG and Valproic Acid improve the phenotype of a new transgenic mouse model of Machado-Joseph Disease” 2012
- “Characterization of a neuronal line stable silencing ataxin-3” 2012
- “Lithium treatment does not ameliorate the phenotype of a new transgenic mouse model of Machado-Joseph Disease. Mouse Models of Disease – Linking the vivo observations to pathology endpoint” 2012
- “Lithium treatment does not ameliorate the phenotype of a new transgenic mouse model of Machado-Joseph Disease” 2012
- “Region-specific transcriptomic profile alterations in a new transgenic mouse model of Machado-Joseph disease” 2011
- “A novel transgenic mouse model of Machado-Joseph Disease: genetic, phenotypic and pathologic similarities with human disease” 2011
- “A novel transgenic mouse model of Machado-Joseph disease: genetic, phenotypic and pathologic similarities with the human disease” 2011
- “A novel transgenic mouse model of Machado-Joseph Disease: autophagy as a potential therapeutical approach” 2010
- “A novel transgenic mouse of Machado-Joseph disease: autophagy as a potential therapeutical approach” 2010
- “Absence of ataxin-3 leads to enhanced stress response in C. elegans” 2010
- “Genetic and pharmacologic modulation of the HSF-1 pathway rescues neuronal proteotoxicity in a C. elegans model of Machado-Joseph disease” 2010
- “Increased thermotolerance and hormesis in the absence of the DUB ataxin-3 in C. elegans” 2010
- “Molecular determinants of ataxin-3 knockouts thermoresistance phenotype” 2010
- “Phenotypical characterization of isu-1 knockdown animals” 2010
- “Increased thermotolerance in the absence of ataxin-3 in C. elegans” 2009
- “ATX-3, CDC-48 and UBXN-5: a new molecular complex in C. elegans” 2008
- “Insights into C. elegans ataxin-3 function in the ubiquitin-proteasome pathway” 2008
-
teses
- When gaining is loosing: insights into the function of ataxin-3 and its perturbation on the context of Machado-Joseph Disease 2014
- Increased thermotolerance in the absence of ataxin-3 in C. elegans 2009
- Estudo de parceiros moleculares da proteína de C. elegans envolvida na doença de Machado-Joseph, ATX-3 2007